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Abstract
Direct in vivo assessment of pancreatic islet-cells for the study of the pathophysiology of diabetes in humans is hampered by
anatomical and technological hurdles. To date, most of the information that has been generated is derived from histological
studies performed on pancreatic tissue from autopsy, surgery, in vivo biopsy or organ donation. Each approach has its advantages
and disadvantages (as summarised in this commentary); however, in this edition ofDiabetologia, Kusmartseva et al (https://doi.
org/10.1007/s00125-017-4494-x) provide further evidence to support the use of organ donor pancreases for the study of human
diabetes. They show that length of terminal hospitalisation of organ donors prior to death does not seem to influence the
frequency of inflammatory cells infiltrating the pancreas and the replication of beta cells. These findings are reassuring,
demonstrating the reliability of this precious and valuable resource for human islet cells research.
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Abbreviation
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Introduction
Insulin-secreting beta cells, sophisticated and unique endo-
crine cells, comprise the majority of cells in the pancreatic
islets. Their failure, owing to the interplay of genetic, epige-
netic and environmental factors, is key to the onset and pro-
gression of type 1 and type 2 diabetes [1, 2]. Therefore, there
is much interest in investigating the properties of beta cells in
health and disease, with the hope of improving strategies for
diabetes prevention and treatment [1–4]. However, direct
evaluation of beta cell features in vivo is substantially imped-
ed by several factors. For instance, the pancreas is located
deep in the abdomen, in close vicinity and/or direct contact
to vital organs and vessels, and this anatomy makes accessi-
bility extremely limited. In addition, despite much ongoing
work, clinical-grade contrast agents and suitable techniques
for beta cell imaging are not currently available [5]. Further,
owing to the relatively small size of islets, their scattered dis-
tribution in the pancreas and the low total amount of beta cells
(≤1–2% of the whole pancreatic mass), it is difficult to study
this organ. As a consequence, most information on islet and
beta cell pathophysiology in humans derives from histological
studies.
Sources of pancreatic tissue
Autopsy samples For over a century since the discovery of the
pancreatic islets in the rabbit by Paul Langerhans [6],
microscopy-based investigations of the human pancreas have
used samples from organs obtained at autopsy [7]. This work
has resulted in pioneering observations, such as the discovery
of lesions in islets from individuals with diabetes, which was
the first evidence for a link between alterations in islet mor-
phology and the disease [8]. Following on, particularly in the
past few decades, changes in islet and/or beta cell mass, vol-
ume and area have been reported in autoptic pancreatic sam-
ples of those with either type 1 and (although with less con-
sistent results) type 2 diabetes [9–12]. Such an approach has
also allowed for the assessment of morphological patterns
associated with beta cell death and, in some cases, beta cell
regeneration [9–12]. One advantage of using pancreases from
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autopsies is the possibility to access the whole gland, which
may permit detailed morphometric studies. However, the
quality of autoptic pancreatic specimens may be jeopardised
by variability in cold ischaemia time (CIT; the time between
organ removal and chilling of the tissue), which in turn could
lead to tissue autolysis and, therefore, limit the morphological
quality of the samples and the stability of their cellular com-
ponents [13].
Samples from surgeryMore recently, pancreatic surgical sam-
ples obtained after removal of portions of the gland (usually
owing to the presence of pancreatic tumours) have been used
in research. This approach has been generally applied for the
comparison of islets and beta cells from those with and with-
out type 2 diabetes, and also to study beta cell traits in indi-
viduals with insulin resistance [14–17]. Obvious advantages
associated with the use of surgical samples are, for instance,
minimal cold ischaemia and the possibility to evaluate insulin
secretion and insulin sensitivity in the patients before and even
after pancreatectomy, for analysis of correlation with histolog-
ical findings. In addition, techniques have been developed for
the in situ study of pancreatic exocrine and endocrine cells,
using tissue slides from surgical pancreas samples [18]. At the
same time, a number of limitations should be taken into ac-
count, such as the possible presence of diabetes caused by the
underlying disorder of the exocrine pancreas (type 3c diabe-
tes, which may be erroneously classified as type 2 diabetes)
[19, 20], the limited amount of tissue yielded, the variable
regions of the pancreas subjected to resection and the possible
influence of the diverse tumours on neighbouring cells.
Laparoscopic-assisted biopsy samples On a few occasions,
pancreatic tissue samples have been obtained by laparoscopic-
assisted biopsy procedures in individuals with recent-onset type
1 diabetes [21–23]. This has allowed for the study of several
morphological, functional and molecular properties of the islets
and the beta cells early in the natural history of the disease, in
samples of very good quality. However, pancreatic biopsy
carries a high risk of complications, such as postoperative
bleeding and leakage of amylase-rich pancreatic juice from
the margins of the resection, which makes the use of this
procedure for research purposes unacceptable in most cases.
Brain-dead organ donation Many researchers have started to
use whole pancreases (or part of them) retrieved from brain-
dead multi-organ donors. The advantages of using such a re-
source include the transplantation-grade quality of the tissue,
better representation of the demographics of the general pop-
ulation, and possible availability of additional tissues, such as
spleen and pancreatic/non-pancreatic lymph nodes [13].
Indeed, islet density, beta cell amount and turnover and beta
cell ultrastructure have been evaluated using donor pancreatic
samples from both non-diabetic and diabetic individuals
(Fig. 1a–c, f), together with the assessment of innate and adap-
tive immune cell presence in the islets (which is presumed to
be implicated in beta cell dysfunction and death) (Fig. 1d, e)
[24–30]. Further, islets isolated by enzymatic digestion or ac-
quired by laser capture microdissection may be obtained from
the same glands that are used for histology and can, therefore,
be characterised in terms of functional, ultrastructural and mo-
lecular features for association studies [31, 32].
Validity of brain-dead organ donor
pancreases for research
For the reasons mentioned above, the use of organ donor
pancreases in research is being extensively implemented by
single research groups and also, very importantly, by dedicat-
ed networks. For example, the Network for Pancreatic Organ
donors with Diabetes (nPOD; www.jdrfnpod.org), which was
started in 2007 by JDRF in the USA, has reported use of organ
donor pancreases in their research. Similarly, the more recent
programme INNODIA (an Innovative Medicines Initiative
[IMI] 2 Joint Undertaking, receiving support from the
European Union’s Horizon 2020 research and innovation
programme and the European Federation of Pharmaceutical
Industries and Associations [EFPIA], JDRF, and the LeonaM.
and Harry B. Helmsley Charitable Trust; https://innodia.eu/)
has also adopted use of these samples. However, there are
some concerns regarding the use of organ donor pancreases.
For instance, the longer the interval between organ removal
and tissue processing for clinical or research purposes (CIT),
the worse the outcome of pancreas transplant or islet isolation
[33]. However, the duration of CIT can be controlled by the
operators and is consistently registered, which should avoid
the use of organs of poor quality caused by excessive CIT
duration. On the contrary, for obvious reasons, research
teams have no control of other typical steps in the organ
donation timeline, such as the duration of hospital admission
prior to brain death and the brain death to organ removal
interval, both of which have been suggested to affect the
properties of pancreatic non-endocrine and endocrine cells.
Importantly, however, in this edition of Diabetologia,
Kusmartseva et al [34] report that duration of hospital time
prior to organ donor death does not affect the frequency of cell
infiltration into the pancreas or the amount of replicating beta
cells, thus reinforcing the validity and value of this precious
resource. The authors studied pancreases from 39 organ do-
nors without a history of diabetes and collected sample sec-
tions from tissue blocks of the different regions (head, body
and tail) of the gland. The donors were age, sex, BMI and
ethnicity-matched in groups of three, and within each group,
individuals varied in terms of duration of hospitalisation stay
prior to organ retrieval (<3 days, 3 to <6 days or ≥6 days). In
addition, the authors gathered information on the medications
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administered prior to death. Single or double immunohisto-
chemistry staining was then performed to identify cells positive
for insulin, the leucocytemarker CD45, themacrophagemarker
CD68 and the replication marker Ki67. The authors found that
there were no differences in CD45+ and CD68+ cell frequencies
between hospitalisation groups, suggesting no major impact of
hospitalisation stay on the amount of these immune cells in the
pancreas. In addition, the interaction of hospitalisation time
with age group of organ donors also did not influence the
amount of infiltrating immune cells. However, they observed
that the frequency of CD45+ cells was lower in the head and the
body vs tail areas. These regional differences have not been
taken into account in a previous study addressing similar issues
[35], which interestingly reported that a significantly higher
infiltration of CD45+ and CD68+ in the body portion of the
pancreas from organ donors, accompanied prolonged life sup-
port (the head and tail were not examined in this report).
Kusmartseva et al also found that length of hospitalisation
prior to organ donation did not significantly influence beta cell
replication, as assessed by evaluating the presence of the
Fig. 1 Representative images, obtained by light or electronmicroscopy, of
pancreatic samples yielded from organ donors. (a) Immunofluorescence
analysis of an islet from a donor without diabetes; insulin containing cells
are in red, glucagon containing cells are in green (M. Suleiman, personal
communication). (b) Immunofluorescence analysis of an islet containing a
beta cell with an apoptotic nucleus (white arrow); insulin containing cells
are in red, the apoptotic nucleus is in green (TUNEL staining). Scale bars
in (a) and (b), 20 μm. (c) An apoptotic beta cell visualised by electron
microscopy; the yellow arrow indicates an apoptotic nucleus with marked
chromatin condensation, the red arrows indicate insulin granules.
Magnification ×10,000. (d, e) Electron micrograph showing immune cells
infiltrating the pancreas. In (d), the yellow arrows indicate a macrophage
and red arrows indicate insulin granules in a beta cell adjacent to the
macrophage. In (e) the yellow arrow points to a mast cell. Scale bars in
(d) and (e), 1μm. (f) Electronmicrograph showing a beta cell with signs of
death associated with altered autophagy (note the cytoplasm engulfed with
lysosomes [multigranular bodies]); the yellow arrow indicates the nucleus
without evidence of apoptotic features, the red arrows point to some
remaining insulin granules. Magnification ×7000. Figure parts (b), (d)
and (e) adapted from [29] with permission from Springer Nature,
copyright 2015; figure parts (c) and (f) adapted from [31] with permission
from Springer Nature, copyright 2009
Table 1 Main advantages and disadvantages of pancreas sources
Source Advantages Disadvantages Overall tissue quality
Autopsy Access to the whole pancreas
Use of autoptic tissue banks
Possible postmortem artefacts Fair to good
Surgery Minimal CIT
Phenotypic characterisation of patients
undergoing surgery
Limited amount of tissue
Type 3c diabetes to be considered
Possible influences of tumour on islet cell traits
Very good
Biopsy The pancreatic tissue source closest to the
in vivo situation
Limited amount of tissue
Complications owing to the procedure
(bleeding, leakage)
Excellent
Organ donation Transplantation-grade procedures
Possibility to prepare isolated islets
Limited information on family and clinical
history
Limited researcher control of steps from donor
hospital admission to tissue processing
Very good
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marker Ki67 in insulin positive cells. Cells positive for both
insulin and Ki67 staining have been previously observed in
surgical pancreatic samples [36] and some (although not all)
studies using samples from organ donor pancreases [35, 36].
Interestingly, analyses with autoptic pancreatic specimens
have shown extremely low or absent amounts of ‘replicating’
beta cells, suggesting that such a finding could, in part, be an
artefact of the postmortem state [37].
Conclusions
In conclusion, whilst each source of pancreatic tissue from
humans has advantages and disadvantages (summarised in
Table 1), evidence is accumulating, showing that organ donor
pancreases are a precious and valuable resource for the study
of the histology and pathophysiology of human islet cells.
Although the process from donor hospital admission to pan-
creas retrieval cannot always be fully controlled, the duration
of hospital stay until brain death (a major step in the organ
donation timeline), does not seem to be associated with sig-
nificant changes in key histological features of the retrieved
pancreas, such as leucocyte and macrophage infiltration, and
frequency of replicating beta cells. In addition, in a previous
study, duration of final hospitalisation was shown not to be
negatively associated with the quality of nucleic acid extracted
from organ donor pancreases [38]. However, it must be noted
that all the studies that have investigated the correlation be-
tween hospital time before brain death and pancreatic histo-
pathological features have been conducted using tissue from
donors without diabetes and it is not known whether similarly
encouraging findings are applicable to organ donors with di-
abetes. Furthermore, it must be taken into account that little
information, if any, is available on the histology of the human
pancreas should the gland come from donors after cardiac
death (i.e. with permanent cessation of circulatory and respi-
ratory functions) [39, 40]. In Europe [41] and in the USA [42]
there are around 10,000 deceased organ donors per year and
only 10–20% of the available pancreases are used for clinical
transplantation. More effort should therefore be made to im-
plement the use of donor pancreases for research purposes.
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